Shrinks In Sneakers

Tag: neurology

  • RFK Jr. Claims He’ll Identify the Cause of Autism by September

    RFK Jr. Claims He’ll Identify the Cause of Autism by September

    In a bold statement this week, Robert F. Kennedy Jr. announced that he will reveal the definitive cause of autism by September. Kennedy, a longtime critic of childhood vaccine programs, did not provide specific scientific details or a research plan, but implied that his administration would prioritize transparency and independent investigations into the condition’s origins.

    The claim has sparked immediate controversy. Autism is a complex neurodevelopmental condition with a strong genetic foundation and a wide range of potential environmental influences—none of which have yielded a singular, definitive cause. The scientific consensus, built over decades of rigorous research, continues to support a multifactorial model rather than a simplistic explanation.

    Many highly intelligent and dedicated scientists have spent years studying autism without identifying a single, unifying cause. One of the recurring issues that arises when politics intersects with science is a resistance to the idea that these are nuanced, multifaceted conditions. It’s not the most satisfying explanation—but it is consistent with the best evidence we have. My fear is that this type of investigation, under political pressure, could prematurely identify a false causal agent—such as vaccines—and reignite a harmful narrative that has already been thoroughly debunked.

    Kennedy’s history of promoting vaccine-autism links adds further concern. The CDC, WHO, and a vast body of peer-reviewed research have all concluded there is no credible evidence connecting vaccines to autism. Suggesting otherwise not only undermines public trust in science and medicine—it risks the health of entire communities by fueling vaccine hesitancy.

    For families and individuals affected by autism, the promise of discovering its origins is understandably compelling. But it’s critical that we approach that pursuit with scientific integrity, not political expediency.

  • Can β-Blockers Really Delay the Onset and Progression of Huntington’s Disease?

    Can β-Blockers Really Delay the Onset and Progression of Huntington’s Disease?

    Huntington’s disease (HD) is a devastating neurodegenerative disorder that affects individuals and their families on multiple levels. Over the years, I’ve worked with many patients suffering from HD, and it’s difficult to overstate the physical, cognitive, and emotional toll this disease takes. Beyond the progressive motor dysfunctions that eventually rob patients of their independence, the neuropsychiatric symptoms, including severe depression, irritability, and even psychosis, can be equally debilitating. Tragically, suicide risk in this population is alarmingly high, particularly in the early stages when patients are still aware of their prognosis.

    One of the greatest challenges we face in treating Huntington’s disease is the lack of disease-modifying treatments. While therapies exist to help manage symptoms, such as tetrabenazine for chorea or antidepressants for mood disturbances, these interventions only address parts of the disease. To date, there has been little that offers hope for slowing its relentless progression.

    However, a recent article published in JAMA titled “β-Blocker Use and Delayed Onset and Progression of Huntington Disease” has introduced a glimmer of hope. The study explored the potential role of β-blockers in altering the course of HD. These medications, commonly prescribed for hypertension and cardiac conditions, may also have neuroprotective properties. According to the study, β-blocker use was associated with delayed onset and slowed progression of Huntington’s disease. The study analyzed data from a cohort of over 1,000 patients, utilizing longitudinal assessments to measure disease onset and progression. Statistical analysis revealed a significant reduction in the rate of disease progression among patients taking β-blockers compared to those who were not, with a hazard ratio of 0.78 (95% CI, 0.65–0.92; p < 0.01). This is a groundbreaking finding because it suggests a readily available and widely used class of medications could have a profound impact on a previously untreatable condition.

    The way β-blockers work to slow the progression of HD isn’t entirely clear, but it’s thought they might help by reducing brain inflammation and preventing damage caused by overstimulated nerve cells. Furthermore, they could potentially mitigate some of the psychiatric symptoms seen in HD, such as aggression and anxiety, by dampening the overactivity of the sympathetic nervous system.

    For those of us who work closely with this patient population, findings like these provide a much-needed sense of optimism. If future research confirms these results, we may see a shift in how HD is managed. Imagine being able to tell a patient, “We have a medication that might slow this disease’s progression.” That could be life-changing for so many individuals and their families.

    This study is an important reminder that even in diseases where hope seems scarce, progress is being made. For me, it reinforces why we never stop searching for answers—because even small steps forward can eventually change lives in ways we never imagined. It also underscores the importance of continued research and innovation in the field of neurodegenerative disorders. For patients with HD, their loved ones, and the clinicians who care for them, this kind of news is invaluable.

    What are your thoughts on the use of β-blockers for HD? Have you seen this approach applied in your practice or with your patients? Let’s continue the conversation and keep hope alive for those impacted by this challenging disease.

  • Want to Slow Parkinson’s Progression? Consider the TEMPO-3 Breakthrough

    Want to Slow Parkinson’s Progression? Consider the TEMPO-3 Breakthrough

    The TEMPO-3 trial focused on the use of rasagiline in patients with early Parkinson’s disease (PD). Rasagiline is a monoamine oxidase-B (MAO-B) inhibitor, which helps to increase dopamine levels by preventing its breakdown, potentially slowing the progression of Parkinson’s disease. Here are the key findings from the TEMPO-3 trial:

    1. Slowed Progression of Symptoms: The trial found that early treatment with rasagiline at a dose of 1 mg/day slowed the progression of motor symptoms compared to delayed treatment, suggesting potential disease-modifying effects.
    2. Improvement in Quality of Life: Patients who received rasagiline earlier in their treatment course experienced an improvement in daily activities and quality of life. This was measured by tools such as the Unified Parkinson’s Disease Rating Scale (UPDRS).
    3. Well-Tolerated: Rasagiline was well-tolerated with a favorable safety profile. The side effects were mild and included headache, joint pain, and flu-like symptoms, but there were no significant safety concerns over the course of the trial.
    4. Delay in Disability: The study hinted at rasagiline’s ability to delay the onset of disability by slowing motor symptom progression, which may result in a reduced need for other symptomatic treatments earlier in the disease course.

    Overall, the TEMPO-3 trial supported rasagiline’s role as a first-line therapy in early Parkinson’s, emphasizing its benefit in delaying motor progression and potentially altering the disease course.

  • Delirium Dilemma: Can Orexin Drugs Be the Game-Changer?

    Delirium Dilemma: Can Orexin Drugs Be the Game-Changer?

    As a psychiatrist, I’ve done countless consults, and one of the most challenging things to explain is that delirium is caused by an underlying medical condition—not a psychiatric one. There’s no specific psychiatric medication to directly treat delirium. Instead, treatment focuses on environmental adjustments, like placing a clock in the room, displaying the date clearly, and providing frequent reorientation to help ground the patient.

    One area where psychiatry might make a difference, though, is in addressing sleep issues. Many patients with delirium also have irregular sleep patterns, which is why melatonin is often suggested. However, when orexin antagonists like Suvorexant came on the market, they offered improvements in both sleep quality and quantity without the risky side effects of benzodiazepines and Z-drugs. These medications became a potential option for preventing and possibly treating delirium in various forms.

    Recently, Suvorexant underwent a phase-3 trial for delirium prevention, but the results weren’t as promising as hoped. While the Suvorexant group did show a lower incidence of delirium in older hospitalized adults compared to the placebo group, the difference wasn’t statistically significant. On the bright side, the drug was linked to significantly lower delirium rates in patients with hyperactive and mixed subtypes of dementia, which may open doors for further exploration in these specific cases.

    Link to the study: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2822422

  • What is Aphasia?

    What is Aphasia?

    Aphasia is an inability to comprehend or formulate language usually due to damage to specific brain regions responsible for these processes. 

    There are two important points here to note: 

    1. Aphasia is the consequence of another brain disorder such as stroke, brain tumor, traumatic brain injury, viral infections like HSV or neurovegetative process (think dementia here). 

    2. There are different types of aphasias, most notably they can be broken down into expressive and receptive aphasia

    To be diagnosed the person must have significant impairment in one or more of the following

    1. Auditory comprehension

    2. Verbal expression

    3. Reading and writing

    4. Functional communication

    About 2 million people are affected by this disorder in the U.S. and strokes account for most of the documented cases. 

    One of the most common presentations is anomic aphasias where individuals have word retrieval failures and cannot express the words they want to say (usually nouns and verbs). Some level of this is seen in all types of aphasia.

    There can be many other presentations including: 

    -inability to comprehend language 

    -inability to pronounce words

    -inability to speak spontaneously

    -inability to read 

    -inability to write 

    The two most common examples: 

    Receptive aphasia (Wernicke’s):

    This is a fluent aphasia where the person can speak in sentences but there is no meaning, unnecessary words, and possibly the creation of new words called neologisms. 

    -They have poor auditory and reading comprehension.

    -There is fluent but nonsensical written or oral expression.

    -Since thy do not comprehend language well they are often unaware of their mistakes. 

    -The area of the brain affected is well known and established it’s the left temporal lobe as indicated in the picture. 

    Expressive aphasia: Broca’s 

    -These individuals will speak in short, meaningful phrases with great effort. It will be noticeable how much effort they are putting into speaking. 

    -They are usually able to understand the speech of others and are aware of the difficulties they are having leading to frustration. 

    -The location of the brain injury is well established, damage to the frontal lobe causes this presentation 

    Primary progressive aphasia 

    -This is a form of dementia 

    -Characterized by gradual loss of language functioning while other cognitive domains such as personality and memory are mostly preserved 

    -It usually starts with sudden word finding difficulties and progresses to reduced ability to form grammatically correct sentences, and impaired comprehension